Biovitrum Creates Rare-Disease Focused Spec Pharma with Swedish Orphan Buy
This article was originally published in The Pink Sheet Daily
Executive Summary
The Swedish biotech pays roughly $500 million for a company with a revenue stream from commercial products as part of its transition into a spec pharma.